Bone Marrow Transplant (BMT)
Bone Marrow Transplant (BMT)
1
| Disease Status and/or Stage | Multiple Myeloma |
|---|---|
| Protocol Title | A Phase 1 Pilot Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed by Autologous Stem Cell Transplant for Patients with Multiple Myeloma |
| PI | Tsiporah Shore, MD |
| Contact | |
| Key Eligibility | Patients with multiple myeloma who have received induction therapy and have had stem cells mobilized in preparation for autologous transplantation will be eligible for this study. Patients are also eligible with relapsed or refractory disease, after attempts at more standard approaches, and with the availability of stem ce |
| Treatment Overview | As a conditioning regimen, patients will receive Melphalan 100 mg/m2 for 2 days and Bendamustine on the second day of Melphalan. The dose of bendamustine is increased depending on the cohort and toxicity. Autologous hematopoietic stem cells will then be infused. The primary objective of this trial is to determine the safety and toxicity of a Melphalan/Bendamustine conditioning regimen. |
2
| Disease Status and/or Stage | Primary Refractory and Relapsed Acute Myelogenous Leukemia |
|---|---|
| Protocol Title | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia |
| PI | Usama Gergis, M.D. |
| Contact | June Greenberg, R.N. 212-746-2651 |
6
| Disease Status and/or Stage | Unrelated Donors |
|---|---|
| Protocol Title | Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors |
| PI | Tsiporah Shore, M.D. |
| Contact | June Greenberg, R.N. 212-746-2651 |
8
| Disease Status and/or Stage | Relapsed Follicular Non-Hodgkin’s Lymphoma |
|---|---|
| Protocol Title | BMT CTN 0701 - Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin’s Lymphoma Beyond First Complete Response. |
| PI | Tsiporah Shore, M.D. |
| Contact | June Greenberg, R.N. 212-746-2651 |
9
| Disease Status and/or Stage | Multiple Myeloma |
|---|---|
| Protocol Title | Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study |
| PI | Mark Tomer, M.D. |
| Contact | June Greenberg, R.N. 212-746-2651 |
| Last updated: January 5, 2011 |  |
